Do analysts prefer RBOT or FEED?

Vicarious Surgical presently has a consensus price target of $7.00, suggesting a potential upside of 10,652.69%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, AMIX or RBOT?

Autonomix Medical is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Autonomix Medical N/A N/A -$16.72M -$74.58 N/A Vicarious Surgical N/A N/A -$63.22M -$6.69 N/A

Is AMIX or RBOT more profitable?

Vicarious Surgical's return on equity of -184.13% beat Autonomix Medical's return on equity. Company Net Margins Return on Equity Return on Assets Autonomix Medical N/A -239.36% -192.46% Vicarious Surgical N/A -184.13% -112.50%

Do analysts recommend BBLG or RBOT?

Vicarious Surgical has a consensus price target of $7.00, indicating a potential upside of 10,652.69%. Given Vicarious Surgical's stronger consensus rating and higher probable upside, analysts plainly believe Vicarious Surgical is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has stronger valuation & earnings, BBLG or RBOT?

Bone Biologics is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bone Biologics N/A N/A -$3.11M -$2.27 N/A Vicarious Surgical N/A N/A -$63.22M -$6.69 N/A

Is BBLG or RBOT more profitable?

Bone Biologics' return on equity of -50.47% beat Vicarious Surgical's return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -50.47% -47.40% Vicarious Surgical N/A -184.13% -112.50%

Do analysts rate BJDX or RBOT?

Vicarious Surgical has a consensus target price of $7.00, suggesting a potential upside of 10,652.69%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts clearly believe Vicarious Surgical is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher earnings & valuation, BJDX or RBOT?

Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bluejay Diagnostics N/A N/A -$6.85M -$11.63 N/A Vicarious Surgical N/A N/A -$63.22M -$6.69 N/A

Is BJDX or RBOT more profitable?

Bluejay Diagnostics' return on equity of -144.27% beat Vicarious Surgical's return on equity. Company Net Margins Return on Equity Return on Assets Bluejay Diagnostics N/A -144.27% -115.00% Vicarious Surgical N/A -184.13% -112.50%

Do analysts recommend DYNT or RBOT?

Vicarious Surgical has a consensus target price of $7.00, indicating a potential upside of 10,652.69%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts clearly believe Vicarious Surgical is more favorable than Dynatronics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Vicarious Surgical (RBOT) Competitors

$0.07 0.00 (-3.41%)

As of 08/10/2026 03:49 PM Eastern

Compare

RBOT vs. FEED, AMIX, BBLG, BJDX, and DYNT

Should you buy Vicarious Surgical stock or one of its competitors? Vicarious Surgical's main competitors and comparable companies include Nanovibronix (FEED), Autonomix Medical (AMIX), Bone Biologics (BBLG), Bluejay Diagnostics (BJDX), and Dynatronics (DYNT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Vicarious Surgical compare to Nanovibronix?

Vicarious Surgical (NYSE:RBOT) and Nanovibronix (NASDAQ:FEED) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Nanovibronix has higher revenue and earnings than Vicarious Surgical. Nanovibronix is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
Nanovibronix	$2.55M	0.99	-$18.18M	-$8.82	N/A

In the previous week, Nanovibronix had 2 more articles in the media than Vicarious Surgical. MarketBeat recorded 2 mentions for Nanovibronix and 0 mentions for Vicarious Surgical. Nanovibronix's average media sentiment score of 0.66 beat Vicarious Surgical's score of 0.00 indicating that Nanovibronix is being referred to more favorably in the news media.

Company	Overall Sentiment
Vicarious Surgical	Neutral
Nanovibronix	Positive

Vicarious Surgical presently has a consensus price target of $7.00, suggesting a potential upside of 10,652.69%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Vicarious Surgical has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 11.1% of Vicarious Surgical shares are owned by company insiders. Comparatively, 12.2% of Nanovibronix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vicarious Surgical has a net margin of 0.00% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
Nanovibronix	-923.20%	-54.25%	-43.10%

Summary

Vicarious Surgical and Nanovibronix tied by winning 7 of the 14 factors compared between the two stocks.

How does Vicarious Surgical compare to Autonomix Medical?

Autonomix Medical (NASDAQ:AMIX) and Vicarious Surgical (NYSE:RBOT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Autonomix Medical is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autonomix Medical	N/A	N/A	-$16.72M	-$74.58	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Autonomix Medical has a beta of -1.16, suggesting that its stock price is 216% less volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

Vicarious Surgical's return on equity of -184.13% beat Autonomix Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autonomix Medical	N/A	-239.36%	-192.46%
Vicarious Surgical	N/A	-184.13%	-112.50%

Autonomix Medical presently has a consensus target price of $42.00, suggesting a potential upside of 352.10%. Vicarious Surgical has a consensus target price of $7.00, suggesting a potential upside of 10,652.69%. Given Vicarious Surgical's higher probable upside, analysts plainly believe Vicarious Surgical is more favorable than Autonomix Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autonomix Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Autonomix Medical had 17 more articles in the media than Vicarious Surgical. MarketBeat recorded 17 mentions for Autonomix Medical and 0 mentions for Vicarious Surgical. Autonomix Medical's average media sentiment score of 0.04 beat Vicarious Surgical's score of 0.00 indicating that Autonomix Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Autonomix Medical	Neutral
Vicarious Surgical	Neutral

10.8% of Autonomix Medical shares are owned by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are owned by institutional investors. 6.2% of Autonomix Medical shares are owned by insiders. Comparatively, 11.1% of Vicarious Surgical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Vicarious Surgical beats Autonomix Medical on 8 of the 13 factors compared between the two stocks.

How does Vicarious Surgical compare to Bone Biologics?

Bone Biologics (NASDAQ:BBLG) and Vicarious Surgical (NYSE:RBOT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

In the previous week, Bone Biologics had 1 more articles in the media than Vicarious Surgical. MarketBeat recorded 1 mentions for Bone Biologics and 0 mentions for Vicarious Surgical. Bone Biologics' average media sentiment score of 0.00 equaled Vicarious Surgical'saverage media sentiment score.

Company	Overall Sentiment
Bone Biologics	Neutral
Vicarious Surgical	Neutral

Bone Biologics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are owned by institutional investors. 5.6% of Bone Biologics shares are owned by company insiders. Comparatively, 11.1% of Vicarious Surgical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bone Biologics is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Vicarious Surgical has a consensus price target of $7.00, indicating a potential upside of 10,652.69%. Given Vicarious Surgical's stronger consensus rating and higher probable upside, analysts plainly believe Vicarious Surgical is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Bone Biologics' return on equity of -50.47% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
Vicarious Surgical	N/A	-184.13%	-112.50%

Summary

Vicarious Surgical beats Bone Biologics on 6 of the 11 factors compared between the two stocks.

How does Vicarious Surgical compare to Bluejay Diagnostics?

Bluejay Diagnostics (NASDAQ:BJDX) and Vicarious Surgical (NYSE:RBOT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are held by institutional investors. 6.1% of Bluejay Diagnostics shares are held by insiders. Comparatively, 11.1% of Vicarious Surgical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Vicarious Surgical has a consensus target price of $7.00, suggesting a potential upside of 10,652.69%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts clearly believe Vicarious Surgical is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Bluejay Diagnostics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Bluejay Diagnostics' return on equity of -144.27% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
Vicarious Surgical	N/A	-184.13%	-112.50%

In the previous week, Bluejay Diagnostics' average media sentiment score of 0.00 equaled Vicarious Surgical'saverage media sentiment score.

Company	Overall Sentiment
Bluejay Diagnostics	Neutral
Vicarious Surgical	Neutral

Summary

Vicarious Surgical beats Bluejay Diagnostics on 8 of the 10 factors compared between the two stocks.

How does Vicarious Surgical compare to Dynatronics?

Dynatronics (NASDAQ:DYNT) and Vicarious Surgical (NYSE:RBOT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Vicarious Surgical has a net margin of 0.00% compared to Dynatronics' net margin of -8.35%. Dynatronics' return on equity of -41.81% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dynatronics	-8.35%	-41.81%	-9.56%
Vicarious Surgical	N/A	-184.13%	-112.50%

4.2% of Dynatronics shares are owned by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are owned by institutional investors. 2.9% of Dynatronics shares are owned by insiders. Comparatively, 11.1% of Vicarious Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Dynatronics had 1 more articles in the media than Vicarious Surgical. MarketBeat recorded 1 mentions for Dynatronics and 0 mentions for Vicarious Surgical. Dynatronics' average media sentiment score of 0.00 equaled Vicarious Surgical'saverage media sentiment score.

Company	Overall Sentiment
Dynatronics	Neutral
Vicarious Surgical	Neutral

Dynatronics has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Vicarious Surgical has a consensus target price of $7.00, indicating a potential upside of 10,652.69%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts clearly believe Vicarious Surgical is more favorable than Dynatronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Dynatronics has higher revenue and earnings than Vicarious Surgical. Vicarious Surgical is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Summary

Vicarious Surgical beats Dynatronics on 7 of the 13 factors compared between the two stocks.

Get Vicarious Surgical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RBOT vs. The Competition

Export

Metric	Vicarious Surgical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$464K	$5.82B	$7.02B	$24.19B
Dividend Yield	N/A	1.78%	2.58%	3.69%
P/E Ratio	-0.01	24.71	269.19	29.02
Price / Sales	N/A	61.03	588.76	20.30
Price / Cash	N/A	33.55	28.89	19.37
Price / Book	0.01	6.21	11.27	4.91
Net Income	-$63.22M	$147.87M	$3.45B	$1.06B
7 Day Performance	N/A	1.04%	1.92%	0.05%
1 Month Performance	N/A	1.61%	-0.58%	2.29%
1 Year Performance	N/A	5.32%	75.49%	20.30%

Vicarious Surgical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RBOT Vicarious Surgical	N/A	$0.07 -3.4%	$7.00 +10,652.7%	-99.3%	$464K	N/A	N/A	210	Gap Up
FEED Nanovibronix	0.9537 of 5 stars	$0.37 +7.7%	N/A	N/A	$2.09M	$2.55M	N/A	20	Gap Up High Trading Volume
AMIX Autonomix Medical	2.6344 of 5 stars	$19.50 +434.2%	$42.00 +115.4%	-63.1%	$1.98M	N/A	N/A	1	Upcoming Earnings Gap Up High Trading Volume
BBLG Bone Biologics	0.8789 of 5 stars	$0.95 +5.0%	N/A	-62.2%	$1.63M	N/A	N/A	2	Upcoming Earnings
BJDX Bluejay Diagnostics	0.6968 of 5 stars	$1.00 +6.1%	N/A	-82.4%	$980K	N/A	N/A	9	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RBOT) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vicarious Surgical (RBOT) Competitors

RBOT vs. FEED, AMIX, BBLG, BJDX, and DYNT

How does Vicarious Surgical compare to Nanovibronix?

Summary

How does Vicarious Surgical compare to Autonomix Medical?

Summary

How does Vicarious Surgical compare to Bone Biologics?

Summary

How does Vicarious Surgical compare to Bluejay Diagnostics?

Summary

How does Vicarious Surgical compare to Dynatronics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RBOT vs. The Competition

Vicarious Surgical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vicarious Surgical (RBOT) Competitors

RBOT vs. FEED, AMIX, BBLG, BJDX, and DYNT

How does Vicarious Surgical compare to Nanovibronix?

Which has better valuation & earnings, RBOT or FEED?

Does the media refer more to RBOT or FEED?

Do analysts prefer RBOT or FEED?

Which has more risk & volatility, RBOT or FEED?

Do insiders & institutionals hold more shares of RBOT or FEED?

Is RBOT or FEED more profitable?

Summary

How does Vicarious Surgical compare to Autonomix Medical?

Which has better earnings & valuation, AMIX or RBOT?

Which has more risk & volatility, AMIX or RBOT?

Is AMIX or RBOT more profitable?

Do analysts recommend AMIX or RBOT?

Does the media refer more to AMIX or RBOT?

Do insiders and institutionals hold more shares of AMIX or RBOT?

Summary

How does Vicarious Surgical compare to Bone Biologics?

Does the media prefer BBLG or RBOT?

Which has more risk and volatility, BBLG or RBOT?

Do insiders & institutionals have more ownership in BBLG or RBOT?

Which has stronger valuation & earnings, BBLG or RBOT?

Do analysts recommend BBLG or RBOT?

Is BBLG or RBOT more profitable?

Summary

How does Vicarious Surgical compare to Bluejay Diagnostics?

Do insiders and institutionals hold more shares of BJDX or RBOT?

Do analysts rate BJDX or RBOT?

Which has more volatility & risk, BJDX or RBOT?

Which has higher earnings & valuation, BJDX or RBOT?

Is BJDX or RBOT more profitable?

Does the media favor BJDX or RBOT?

Summary

How does Vicarious Surgical compare to Dynatronics?

Is DYNT or RBOT more profitable?

Do insiders & institutionals believe in DYNT or RBOT?

Does the media favor DYNT or RBOT?

Which has more volatility & risk, DYNT or RBOT?

Do analysts recommend DYNT or RBOT?

Which has preferable earnings and valuation, DYNT or RBOT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RBOT vs. The Competition

Vicarious Surgical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools